Mineralys Therapeutics presented new data on lorundrostat at ASN Kidney Week 2026 in Denver, Colorado, from the Phase 3 Launch-HTN trial. Systolic blood pressure reductions were similar in participants with and without CKD across Stages 1-3. At week 12, lorundrostat reduced placebo-adjusted systolic blood pressure by 9.6 mmHg in participants with CKD and 12.2 mmHg in those without. In participants with CKD and baseline albuminuria, the urine albumin-to-creatinine ratio fell 52.2% versus placebo. The drug is under FDA review for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on manilatimes.net ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- New bipartisan bill aims to speed up clinical trials for rare disease treatments
Bipartisan Reps. Jake Auchincloss (D) and Morgan Griffith (R) introduced the "Faster Clinical Trials Act" to speed up studies of rare disease treatments, one week after the FDA unveiled a new initiative for these drugs. The bill would create a network of reusable clinical trial sites and a "Center for Clinical Trial Innovation" at the FDA, with up to $75 million in annual funding over five years. Its goal is to cut trial costs and enrollment time by at least 30%, and to let patients receive experimental drugs at their regular doctor's office, with progress tracked through Zoom, electronic health records or wearables. Griffith said this would also help patients who live hours away from medical centers.
- Viatris Receives U . S . FDA Approval for RYZUMVI® for the Treatment of Presbyopia
The U.S. FDA has approved Viatris' RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia, the age-related loss of near focusing ability, in adults. The drug was already approved in the U.S. for pharmacologically induced mydriasis, and the new approval expands its use. Viatris holds exclusive U.S. commercialization rights under a licensing deal with Opus Genetics and is exploring a U.S. partner to commercialize RYZUMVI for presbyopia. The most common ocular side effects reported for presbyopia were conjunctival hyperemia (21%) and instillation site irritation (16%), and the drug is not recommended for patients with active ocular inflammation.
- 2 Under-the-Radar Stocks to Buy and Hold
The author sees Axsome Therapeutics (AXSM) and Exelixis (EXEL) as attractive biotech stocks despite less investor attention than leading AI companies. Axsome's Auvelity sales rose 51% year over year to $180.3 million in the second quarter, about 82.6% of the company's $218.4 million revenue, and the drug recently gained approval for Alzheimer's disease agitation and is in a Phase 3 study for smoking cessation. Sunosi sales grew 20% to $35.8 million, and an AXS-12 application could be approved by May 2027. Exelixis posted $628.7 million in second-quarter revenue, up almost 11%, with its main drug Cabometyx protected from U.S. generics until at least 2030. The FDA extended the review for zanzalintinib to March 3, 2027, but the author believes approval remains likely.
- FDA Alert Follows Death Linked to Edwards Device - Orange County Business Journal
The FDA last week issued a safety notice for certain delivery systems used in Edwards Lifesciences' Sapien M3 transcatheter mitral valve replacement, after three balloon bursts occurred during inflation. As of Oct. 5, Edwards reported three incidents, including one death and one serious injury. The company told customers to stop using and return devices from four lot numbers of its Commander M delivery systems. Since the Oct. 15 alert, Edwards shares (EW) have fallen 1.3% to $86.94, with a market cap of about $50 billion.
- Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are near one-year highs, supported by an improving earnings outlook, positive trial data, relatively attractive valuations, and a shift out of crowded AI/tech trades. The State Street Health Care Select Sector SPDR ETF (XLV) rose 23.2% over six months (as of Oct. 20, 2026), versus about 9.2% for the State Street SPDR S&P 500 ETF Trust (SPY). S&P 500 healthcare companies are expected to post double-digit earnings growth from Q4 2026 through 2027, and sector M&A value has reached nearly $284 billion this year, approaching 2025's $306 billion. Notable 2026 readouts include Eli Lilly's retatrutide (28.3% average weight loss over 80 weeks at the 12-mg dose) and Vertex's povetacicept (49.8% proteinuria reduction vs. placebo at Week 36). The article also profiles the VanEck Biotech ETF (BBH, up 30.8% YTD) and Invesco Biotechnology & Genome ETF (PBE, up 20.5% YTD).
- Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have launched a strategic collaboration to explore AI in clinical research, starting with lung health studies. The focus is on digital patient twins, computer-based models of individual patients built from clinical data, to test whether they can forecast disease progression and patient outcomes. The companies will assess whether these models can serve as synthetic or hybrid control arms, potentially reducing the number of participants in control groups, streamlining trial design and speeding up evidence generation. If successful, the approach could improve drug development efficiency and allow more trial participants to receive experimental treatments. The alliance also covers data centre modernisation and technical security, with further joint initiatives under review in animal health and commercial processes.
Related markets
Latest news
- Newegg Now Offers NVIDIA RTX Spark Laptops in the U.S. and Canada
Newegg announced that NVIDIA RTX Spark laptops are now available to order in the U.S. and Canada via Newegg.com and Newegg.ca, starting with the MSI Prestige N16 Flip AI+ priced from $3,299 USD. RTX Spark combines NVIDIA AI, RTX graphics and unified memory in one Windows PC, designed to run larger AI models locally and handle creative work, development and gaming. Creators get accelerated 3D rendering and AV1 encoding, while gamers get ray tracing, DLSS and Reflex in supported games. Purchases are limited to one unit per customer, and Newegg says it will add more systems as partners bring them to market.
- Meta’s capital-raising plans expose a major weakness in the AI boom
Meta (NASDAQ:META) shares fell 7% on Thursday despite strong earnings, after the company unveiled plans to issue a new class of non-voting Class C stock. In its filing, a special committee cited an increasingly challenging environment for raising capital, pointing to recent and anticipated large raises by Alphabet, SpaceX, Anthropic and OpenAI to fund similar AI growth. Meta said it currently has sufficient capital for its needs but wants more financing flexibility going forward, with the new shares available as early as the end of 2026. The article notes Meta raised its 2026 capital expenditure forecast to $135–145 billion, while third-quarter revenue grew 26% to $64.6 billion and capex reached $34.91 billion, pushing free cash flow negative.
- The AI Bottleneck Takes Many Forms. These 7 Stocks Will Benefit.
AI growth is hitting bottlenecks in chips, memory, power, connectivity and cooling, and the Nasdaq-100 Technology Sector Index fell more than 5% in the past week. The article highlights seven companies tackling these constraints. Nvidia still faces GPU supply limits as it ramps Blackwell and Vera Rubin, while Micron, a high-bandwidth memory maker, reported fiscal fourth-quarter 2026 revenue of $54.23 billion versus $11.32 billion a year earlier. Lumentum guided to revenue of $1.225 billion to $1.275 billion for the next quarter, Coherent's data center and communications segment hit $1.615 billion, and GE Vernova reported $24.2 billion in orders. Bloom Energy's Oracle deal covers up to 2.8 gigawatts of on-site fuel cell capacity, and Vertiv supplies cooling systems, though expanding production remains a challenge.
- Same Playbook, Different Silicon: Broadcom Holds the Throne, Marvell Plays the AMD Challenger.
Broadcom and Marvell both beat AI estimates and raised guidance, but Broadcom operates at much larger scale, with AI semiconductor revenue of $16.70 billion, up 221% year over year and 56% of total revenue. Custom XPUs supplied 73% of its AI revenue, while gross margin slipped to 75% and operating margin reached 67.9%. Marvell reported $2.74 billion in revenue, up 36.5%, with data center sales at 79% of the total, and its Google deal includes a warrant for up to 7% of its shares. Broadcom guided to Q4 revenue of about $34.8 billion and AI revenue of about $21.7 billion, while Marvell guided to $3.15 billion and plans about $1 billion in supplier prepayments. Marvell is up 163.4% year to date, while Broadcom is down 6.09%.
- Arm’s Ready-Made Blueprints: The Blueprint Attack on Marvell’s Challenger Crown
Arm reported fiscal first-quarter revenue of $1.29 billion, up 22%, and says AGI CPU demand now exceeds $2 billion, though locked-in supply covers only the initial $1 billion. Marvell posted record revenue of $2.739 billion, up 37%, with data center sales at 79% of the total. The article argues Arm's ready-made compute subsystems and AGI CPU could let hyperscalers skip some custom design work that Marvell sells, and Arm may accept thinner margins, with first-generation AGI CPU gross margin expected in the high 30% range, maybe low 40s, versus Marvell's 58.9% non-GAAP gross margin. Marvell's non-GAAP operating margin rose to 36.6% from 34.8%, while Arm trades at about 248 times earnings. Over the past month, Arm fell 36.94% and Marvell lost 14.8%.
- Alphabet Solves the AI Infrastructure Bottlenecks Competitors Can’t Buy with Debt
The author argues Alphabet (NASDAQ:GOOGL) has an edge by owning its TPU chips, power, private fiber networks and multimodal training data, while rivals must rent them. Google Cloud revenue in Q2 2026 rose 82% to $24.77 billion, and operating income climbed 30.38% to $40.77 billion. The article cites a trailing P/E of 14, debt-to-equity of 0.14, and a 5% quarterly dividend increase to $0.22, and compares these with higher P/E ratios at Microsoft and Amazon. Risks noted include Q2 capital expenditures of $44.92 billion, which pushed free cash flow to -$5.86 billion, long-term debt rising to $98.2 billion, and $49.6 billion raised in equity. After the stock fell 7.16% over the week to $324.22, the author says they bought more shares.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.